universal dual specificity CD19/CD20 or CD22 CAR-T cell immunotherapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for universal dual specificity CD19/CD20 or CD22 CAR-T cell immunotherapy, covering 2018-01-16 to 2018-01-16. Get the full timeline:
Most recent: Clinical Trial Update: A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma [Phase 1, Phase 2]